L26/P-801 Clomiphene citrate is associated with improved ovarian response in GnRH Antagonist cycles: a propensity score-matched study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von B. Demir und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is addition of clomiphene citrate to a GnRH antagonist protocol associated with increased total and mature oocyte yields without compromising embryological outcomes in freeze-all cycles? Summary answer Clomiphene citrate co-administration in GnRH antagonist cycles is associated with enhanced follicular recruitment and increased total and mature oocyte yields without adverse embryological outcomes. What is known already Optimizing ovarian response during controlled ovarian stimulation is essential to improving treatment performance in assisted reproductive technologies, as oocyte number and developmental competence directly influence outcomes. Co-administration of clomiphene citrate (CC), a selective estrogen receptor modulator, enhances endogenous stimulation via the hypothalamic–pituitary axis while suppressing premature luteinizing hormone surges. Hypothetically, augmented endogenous stimulation may facilitate recruitment of smaller follicular cohorts. However, the effects of continuous CC use during stimulation on ovarian response and embryological performance remain incompletely defined. Study design, size, duration This retrospective cohort study analyzed IVF cycles undergoing ovarian stimulation with either a GnRH antagonist protocol alone or combined with CC. Propensity scores were estimated using logistic regression including female age, body mass index, total antral follicle count, and anti-Mullerian hormone. Independent predictors of mature oocyte yield were assessed using negative binomial regression, with treatment protocol as the primary predictor adjusted for age and ovarian reserve. Results presented as incidence rate ratios with 95% intervals. Participants/materials, setting, methods The study population between January 2021 and May 2025 comprised 6,996 patients, including 5,888 in the GnRH antagonist group and 1,108 in the CC–GnRH antagonist group, reflecting a marked imbalance in group sizes (1:5.3). Propensity score matching was performed 1:1 without replacement to estimate the average treatment effect on the treated, resulting in a final matched cohort of 870 patients (435 per group). Main results and the role of chance Multivariable negative binomial regression analysis demonstrated that the CC–GnRH antagonist protocol was independently associated with a significantly higher mature oocyte yield compared with the GnRH antagonist protocol (β = 0.129, p = 0.026). After adjustment for female age and total antral follicle count, the adjusted incidence rate ratio (IRR) was 1.14 (95% CI 1.01–1.28), corresponding to an approximate 14% increase in the expected number of mature oocytes with CC co-administration. On the day of trigger, estradiol and luteinizing hormone levels were significantly higher in CC-GnRH antagonist cycles, while total gonadotropin consumption was significantly lower compared with antagonist-only cycles. Stimulation duration, however, was significantly longer in the CC group. (12.80 vs. 11.99 days). Despite prolonged stimulation, ovarian response efficiency was improved with CC co-administration. The follicle-to-oocyte index (FOI) was significantly higher in the CC–GnRH antagonist group (median 100.0% vs. 93.5%; p = 0.005), with a small to moderate effect size (rank-biserial correlation rb = 0.11; 95% CI 0.03–0.18). In contrast, the follicular output rate (FORT) did not differ significantly between groups (p = 0.383). Fertilization rates were significantly lower in CC cycles (median 77.8% vs. 89.7%; p = 0.041), whereas blastulation rates and cycle cancellation rates were comparable between the two protocols. Limitations, reasons for caution This study is limited by its retrospective design, and unmeasured confounding cannot be entirely excluded despite propensity score matching. Pregnancy outcomes were not evaluated, as the study focused on ovarian stimulation performance and embryological outcomes. Wider implications of the findings The results support further consideration of clomiphene citrate as part of ovarian stimulation strategies aimed at improving efficiency, as reflected by enhanced follicular recruitment and oocyte yield, while maintaining embryological performance in freeze-all IVF cycles. Trial registration number Yes
Zitieren
APA
Demir, B., Dundar, B., Tohma, Y., Gultomruk, M., Bozdag, G., Boynukalın, K., & Bahceci, M. (2026). L26/P-801 Clomiphene citrate is associated with improved ovarian response in GnRH Antagonist cycles: a propensity score-matched study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1128
Vancouver
Demir B, Dundar B, Tohma Y, Gultomruk M, Bozdag G, Boynukalın K, et al. L26/P-801 Clomiphene citrate is associated with improved ovarian response in GnRH Antagonist cycles: a propensity score-matched study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1128
BibTeX
@article{Demir2026,
author = {Demir, B. and Dundar, B. and Tohma, Y.A. and Gultomruk, M. and Bozdag, G. and Boynukalın, K. and Bahceci, M.},
title = {L26/P-801 Clomiphene citrate is associated with improved ovarian response in GnRH Antagonist cycles: a propensity score-matched study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1128}
}
EUVIMED